The non-small cell lung cancer drugs market will register a CAGR of over 13% by 2023

Tuesday, March 19, 2019 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, March 18, 2019 /PRNewswire/ -- About this marketThe increasing prevalence and incidence of non-small cell

lung cancer are one of the primary factors driving the global non-small cell lung cancer drugs market growth. The growing risk factors such as cigarette smoking, air pollution, secondary smoking, and occupational exposure is increasing the incidence
of non-small cell lung cancer across the world. This will lead to an increase in the demand for non-small cell lung cancer drugs. Analysts have predicted that the non-small cell lung cancer drugs market will register a CAGR of over 13% by 2023.Download the full report: https://www.reportbuyer.com/product/5756634 Market OverviewStrong drug pipeline and recent drug approvalsOne of the growth drivers of the global non-small cell lung cancer drugs market is the strong drug pipeline and recent drug approvals. The development of new drugs and their approvals are helpful for the treatment of non-small lung cancer, which is expected to drive the market during the forecast period.The high cost of treatmentOne of the challenges in the growth of global non-small cell lung cancer drugs market is the high cost of treatment. Non-small cell lung cancer can be treated by surgery, chemotherapy, radiation therapy, targeted therapies, and immunotherapy which is very costly. Therefore, the high cost of treatment for non-small cell lung cancer will hamper the growth of the market during the forecast period.For the detailed list of factors that will drive and challenge the growth of the non-small cell lung cancer drugs market during the 2019-2023, view our report.Competitive LandscapeThe market appears to be moderately fragmented and with the presence of several vendors. The vendors in the market are using predictive biomarkers for the development of cost-effective therapies with improved clinical benefits. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.Download the full report: https://www.reportbuyer.com/product/5756634 About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: sarah@reportbuyer.com Tel: +1 (718) 213 4904 Website: www.reportbuyer.com

Cision View original content:http://www.prnewswire.com/news-releases/the-non-small-cell-lung-cancer-drugs-market-will-register-a-cagr-of-over-13-by-2023-300814211.html

SOURCE ReportBuyer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store